Ritu Baral
Stock Analyst at TD Cowen
(0.98)
# 3,745
Out of 4,911 analysts
36
Total ratings
40%
Success rate
-12.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $38.67 | +13.78% | 1 | Feb 5, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $8.80 | +2.27% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.33 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.10 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $36.27 | +115.05% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $328.81 | +12.83% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $103.95 | -5.72% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $298.40 | +30.70% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $10.24 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $11.93 | +1,366.89% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $23.25 | -9.68% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.50 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.50 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.57 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.81 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.05 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.57 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.53 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $735.01 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $38.67
Upside: +13.78%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $8.80
Upside: +2.27%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.33
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $36.27
Upside: +115.05%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $328.81
Upside: +12.83%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $103.95
Upside: -5.72%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $298.40
Upside: +30.70%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $10.24
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $11.93
Upside: +1,366.89%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $23.25
Upside: -9.68%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.50
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.50
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.81
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.05
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.57
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $735.01
Upside: -